A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

In both Part A and Part B, treatments will be administered in two phases starting with an
induction phase followed by a maintenance phase. During the induction phase, treatments will
be administered in 42-day cycles in Cycles 1 through 4. Following completion of Cycle 4 in
the induction phase, subjects with non-progressive disease will enter the maintenance phase.
During the maintenance phase, treatments will be administered in 28 day cycles. Subjects may
continue CC-90002 for up to a maximum of 2 years (eg, induction phase Cycles 1 through 4 and
maintenance phase Cycles 5 through 24) or until clinically significant disease progression,
the occurrence of intolerable toxicity, or physician/subject decision to discontinue
CC-90002, whichever comes first.

Inclusion Criteria:

1. Men and women ≥ 18 years of age, at the time of signing the informed consent form
(ICF).

2. Relapsed and/or primary refractory Acute Myeloid Leukemia (AML) or Myelodysplastic
Syndrome (MDS) with subtype refractory anemia with excess blasts (RAEB)-2 defined as
high or very high-risk that is recurrent or refractory, or the patient is intolerant
to established therapy.

3. Subject consents to hospitalization for first (Cycle 1 Day 1) dose of CC-90002 and for
72 hours after.

4. Subject consents to serial bone marrow aspiration and biopsies as specified.

5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2.

6. Eligible study subjects must exhibit acceptable liver, renal, and coagulation function
as assessed by laboratory tests.

7. Females and males must practice true abstinence or agree to contraceptive methods
throughout the study, and for up to 8 weeks following the last dose of CC 90002.

Exclusion Criteria:

1. Active central nervous system (CNS) leukemia or known CNS leukemia.

2. Immediately life-threatening, severe complications of leukemia.

3. Impaired cardiac function or clinically significant cardiac diseases.

4. Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

5. Prior autologous hematopoietic stem cell transplant ≤ 3 months.

6. Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or
reduced intensity conditioning ≤ 6 months.

7. Systemic immunosuppressive therapy post HSCT or with clinically significant
graft-versus-host disease (GVHD).

8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives
or 4 weeks whichever is shorter.

9. Major surgery ≤ 2 weeks and recovered from any clinically significant effects of
recent surgery.

10. Pregnant or nursing females.

11. Known HIV infection.

12. Known chronic hepatitis B or C (HBV/HCV) infection.

13. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.

14. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.

15. History of concurrent second cancers requiring active, ongoing systemic treatment.

16. Subjects for whom potentially curative anticancer therapy is available.